| Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1 H Johnen, S Lin, T Kuffner, DA Brown, VWW Tsai, AR Bauskin, L Wu, ... Nature medicine 13 (11), 1333-1340, 2007 | 634 | 2007 |
| Basic mechanisms responsible for osteolytic and osteoblastic bone metastases TA Guise, KS Mohammad, G Clines, EG Stebbins, DH Wong, LS Higgins, ... Clinical cancer research 12 (20), 6213s-6216s, 2006 | 634 | 2006 |
| Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling EG Bluemn, IM Coleman, JM Lucas, RT Coleman, S Hernandez-Lopez, ... Cancer cell 32 (4), 474-489. e6, 2017 | 595 | 2017 |
| The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis JM Lucas, C Heinlein, T Kim, SA Hernandez, MS Malik, LD True, ... Cancer discovery 4 (11), 1310-1325, 2014 | 491 | 2014 |
| Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway TM Morgan, TD Koreckij, E Corey Current cancer drug targets 9 (2), 237-249, 2009 | 368 | 2009 |
| Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers A Kumar, TA White, AP MacKenzie, N Clegg, C Lee, RF Dumpit, ... Proceedings of the National Academy of Sciences 108 (41), 17087-17092, 2011 | 305 | 2011 |
| Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer E Corey, LG Brown, JE Quinn, M Poot, MP Roudier, CS Higano, ... Clinical Cancer Research 9 (1), 295-306, 2003 | 302 | 2003 |
| Osteoprotegerin and rank ligand expression in prostate cancer JM Brown, E Corey, ZD Lee, LD True, TJ Yun, M Tondravi, RL Vessella Urology 57 (4), 611-616, 2001 | 302 | 2001 |
| Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. NPS Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I ... Nat Commun., 2014 | 282 | 2014 |
| Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer MP Labrecque, IM Coleman, LG Brown, LD True, L Kollath, B Lakely, ... The Journal of clinical investigation 129 (10), 4492-4505, 2019 | 273 | 2019 |
| Androgen receptor splice variants determine taxane sensitivity in prostate cancer M Thadani-Mulero, L Portella, S Sun, M Sung, A Matov, RL Vessella, ... Cancer research 74 (8), 2270-2282, 2014 | 267 | 2014 |
| LuCaP prostate cancer patient‐derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics HM Nguyen, RL Vessella, C Morrissey, LG Brown, IM Coleman, ... The Prostate 77 (6), 654-671, 2017 | 259 | 2017 |
| Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells E Corey, JE Quinn, F Bladou, LG Brown, MP Roudier, JM Brown, ... The Prostate 52 (1), 20-33, 2002 | 243 | 2002 |
| Elevation of cytokine levels in cachectic patients with prostate carcinoma J Pfitzenmaier, R Vessella, CS Higano, JL Noteboom, D Wallace Jr, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 220 | 2003 |
| LuCaP 35: a new model of prostate cancer progression to androgen independence E Corey, JE Quinn, KR Buhler, PS Nelson, JA Macoska, LD True, ... The Prostate 55 (4), 239-246, 2003 | 212 | 2003 |
| Cathepsin K mRNA and protein expression in prostate cancer progression KD Brubaker, RL Vessella, LD True, R Thomas, E Corey Journal of Bone and Mineral Research 18 (2), 222-230, 2003 | 194 | 2003 |
| Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models MI Suominen, KM Fagerlund, JP Rissanen, YM Konkol, JP Morko, ... Clinical Cancer Research 23 (15), 4335-4346, 2017 | 188 | 2017 |
| Prostate cancer reactivates developmental epigenomic programs during metastatic progression MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ... Nature genetics 52 (8), 790-799, 2020 | 184 | 2020 |
| Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress MD Nyquist, A Corella, I Coleman, N De Sarkar, A Kaipainen, G Ha, ... Cell reports 31 (8), 2020 | 179 | 2020 |
| A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening ML Beshiri, CM Tice, C Tran, HM Nguyen, AG Sowalsky, S Agarwal, ... Clinical Cancer Research 24 (17), 4332-4345, 2018 | 175 | 2018 |
Ilsa ColemanResearch Scientist, Fred Hutchinson Cancer Research CenterVerified email at fhcrc.org
